Clinical Trials Logo

Filter by:
NCT ID: NCT04874584 Completed - Quality of Life Clinical Trials

Culturally Tailored Nurse Coaching Study for Cancer Symptom Management

Start date: October 27, 2021
Phase: N/A
Study type: Interventional

The purpose of the study is to see whether or not a telephone/ text message intervention, delivered by a registered nurse, is helpful in managing symptoms and can also prevent dehydration caused by chemotherapy treatment when given together for patients with metastatic breast, colon, lung or prostate cancer.

NCT ID: NCT04874350 Completed - Sarcopenia Clinical Trials

A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia

Start date: November 30, 2021
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of LPCN 1148 in men with cirrhosis of the liver and sarcopenia.

NCT ID: NCT04874272 Completed - Clinical trials for Health Personnel Attitude

Feasibility and Acceptability of a Chaplain-Led Post-Code Debrief Intervention

PCD
Start date: November 6, 2020
Phase: N/A
Study type: Interventional

The objective of this study is to increase the frequency and effectiveness of post code debriefs by piloting a novel intervention tool and partnering clinicians with board certified chaplains trained to facilitate group processes. A post code debrief will involve two aspects: a technical debrief (a discussion to process the technical, procedural aspects of a medical code/cardiopulmonary arrest), which will be led by a clinician, and an emotional debrief (a discussion to process the emotional, existential impact of a medical code/cardiopulmonary arrest), which will be led by a chaplain.

NCT ID: NCT04874233 Completed - Clinical trials for NASH - Nonalcoholic Steatohepatitis

Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers

Start date: April 19, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2a, randomized, parallel-group, placebo-controlled, double-blind, repeated-dose study to evaluate the safety and efficacy of three oral dose levels of HU6 compared to placebo over the course of 61 days in subjects with high BMI and evidence of elevated liver fat.

NCT ID: NCT04874155 Completed - Clinical trials for Restless Legs Syndrome

Noninvasive Peripheral Nerve Stimulation for Medication-Refractory Primary RLS (The RESTFUL Study)

Start date: May 6, 2021
Phase: N/A
Study type: Interventional

Multi-center, prospective double-blind randomized controlled pivotal study of noninvasive peripheral nerve stimulation (NPNS) with the NTX100 Neuromodulation System for patients with medication-refractory moderate-severe primary RLS

NCT ID: NCT04874077 Completed - Clinical trials for Major Depressive Disorder

Using Voice Biomarkers to Predict the Likelihood of Major Depressive Disorder

Start date: April 21, 2021
Phase:
Study type: Observational

Major Depressive Disorder (MDD) is the leading cause of disability worldwide. Depression and anxiety disorders are among the most prevalent of all mental disorders, with an estimated annual prevalence of 9.7% and 18.1% respectively. It has been known for the last 100 years that depression and anxiety both likely affect vocal acoustic properties. In 1921, Emil Kraepelin, characterized depressed patient's voices as having a lower pitch, lower volume, lower rate of speech, more monotony of prosody as well as more hesitations, stuttering, and whispering. Mechanistically, it is possible that the neural circuitry involved in the pathophysiology of mood and anxiety disorders impinge upon the neural circuit involved in speech production, affecting qualities that include rate, prosody, speech latency and other paralinguistic features. Thus, acoustic features of speech may be one of the more readily accessible biomarkers for these conditions. Given this understanding, the investigators sought to develop a passive vocal biomarker instrument for depression and anxiety screening that could markedly expand access as well as standardize the quality of screening in primary care settings.

NCT ID: NCT04873947 Completed - Hypoxia Clinical Trials

Belun SpO2 Accuracy Comparison to Arterial Blood CO-Oximetry

Start date: August 25, 2020
Phase:
Study type: Observational

This study was a comparative, single-center, non-randomized study conducted to evaluate the SpO2 accuracy per standards and guidelines identified above for SpO2 accuracy for pulse oximetry equipment over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison. Testing was conducted under normal office environment conditions.

NCT ID: NCT04873817 Completed - Pain Clinical Trials

Real-World Outcomes Study on Subjects Treated With Radiofrequency Ablation

ROSTRA
Start date: June 29, 2021
Phase:
Study type: Observational

ROSTRA is an international, prospective, non-randomized, single-arm, multi-center, and post-market study to collect real-world safety and effectiveness data on Abbott's IonicRF™Generator and compatible RFA accessories. This post-market study is intended to satisfy EU MDR requirements. The study will enroll up to 180 subjects at up to 10 sites in Europe and the United States. The total duration of the study is expected to be 19 months, including enrollment, data collection from all subjects, and study closeout.

NCT ID: NCT04873609 Completed - Hepatitis C Clinical Trials

Electronic Record Assimilation and Subsequent Eradication of Hepatitis C

ERASE-C
Start date: May 1, 2019
Phase: N/A
Study type: Interventional

Given the disproportionately high risk of chronic hepatitis C virus (HCV) infection in the baby boomer cohort, population-based screening has been demonstrated cost effective. Compared to point-of-care testing, however, bulk health messages with coupled lab requisitions delivered directly to patients meeting screening criteria via patient portals could improve HCV screening at minimal cost.

NCT ID: NCT04873453 Completed - Clinical trials for Alcohol Use Disorder

CBD for the Treatment of Alcohol Use Disorder

Start date: August 30, 2021
Phase: Phase 2
Study type: Interventional

This is a double-blind, placebo-controlled, parallel group study designed to assess the efficacy of full spectrum cannabidiol (CBD) and broad spectrum CBD, compared to a placebo control (PC), to reduce drinking in participants with moderate alcohol use disorder according to the DSM-V. If eligible for the study, subjects will be randomized to receive one of the conditions for 8 weeks.